Antibody drug conjugates have not yet lived up to their potential, but there is hope – if we turn to the right solutions and techniques.

The challenge of convincing senior staff to invest in continuous bioprocessing.

A generic and inexpensive way to seperate chiral molecules: magnets

Will President Trump’s prices plan deliver for Americans patients?

Pharma TV ads are getting longer, less humorous and more nostalgic — while containing fewer facts.

Could artificial intelligence help repurpose old drugs for suffers of the degenerative disorder?

Concerns abound that post-Brexit border delays could turn the UK into a “second tier state for pharmaceutical imports.”

Regulators step in to stop stem cell clinics from marketing unproven therapies.

The cell therapy industry faces a number of complex problems. Fortunately, they’re good problems to have.

Streamlined workflows help scientists plot a course for painless peptide mapping